Hycor Gets FDA Approval to Market New Allergy Test

Hycor Biomedical Inc. has received approval from the federal Food and Drug Administration to market a line of single-day allergy tests.

The new tests cut in half the time it takes to receive results from an enzyme immuno-assay test, the most common type of test used in doctors’ offices, said Reg Jones, a company spokesman.

Hycor does not necessarily expect to increase sales with the new test; it already has revenue of $7 million in the market.

“This will keep us a step ahead of our competitors,” Jones said. “We are trying to prevent a loss of sales, and perhaps get others to switch.”

Hycor’s stock closed at $7.13 a share Thursday, up 75 cents in over-the-counter trading.

Hycor is a Garden Grove biotechnology company that specializes in medical diagnostic products. Jones said the company will apply the single-day test to each of its 250 tests for allergens.